2. Select Ongoing Neoadjuvant Immunotherapy Trials Adjuvant Immunotherapy A number of completed and ongoing trials are solely looking at adjuvant immunotherapy involving each of the major ICIs ( Table 3 ). The only large adjuvant study
Search Results
Page:12
Perioperative Systemic Therapy for Resectable Non–Small Cell Lung Cancer
Bharathi Muthusamy, Pradnya D. Patil, and Nathan A. Pennell
Counterpoint: The Case Against Adjuvant High-Dose Interferon-α for Melanoma Patients
Paul B. Chapman
High dose interferon-α (HD IFN) is approved by the United States Food and Drug Administration for adjuvant treatment of patients with stage III melanoma after complete surgical resection. Despite this, clinicians and patients around the world and in many parts of the US have failed to embrace this treatment option because of the lack of overall survival benefit and minimal other clinical benefits seen in randomized trials, combined with the therapy's substantial toxicity. This article reviews the data from the randomized trials that lead to this conclusion and discuss why arguments often advanced in favor of using HD IFN are not persuasive. New treatment options are needed for adjuvant therapy of melanoma. In the meantime, the data from the randomized trials make it difficult for many clinicians and patients to have enthusiasm for adjuvant HD IFN.
Updates in the Systemic Therapy Options for Clear Cell and Non–Clear Cell Renal Cell Carcinoma
Presented by: Philippe E. Spiess, Peter A.S. Johnstone, and Eric Jonasch
experienced disease progression. Most studies of adjuvant tyrosine kinase inhibitors (TKIs) for high-risk localized RCC with clear cell histology have been negative, but adjuvant immunotherapy has shown promise. Several negative studies of adjuvant
Point: Interferon-α for Adjuvant Therapy for Melanoma Patients
Michael S. Sabel and Vernon K. Sondak
allogeneic cell vaccine correlates with improved survival in recurrent metastatic melanoma . Ann Surg Oncol 2002 ; 9 : 486 – 492 . 47 Sondak VK Liu PY Tuthill RJ . Adjuvant immunotherapy of resected, intermediate-thickness, node
Where Are We With Adjuvant Therapy of Stage III and IV Melanoma in 2009?
Leslie A. Fecher and Keith T. Flaherty
melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine . Ann Surg 1992 ; 216 : 463 – 482 . 41 Sondak V Liu P Tuthill R . Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an
Management of Patients With Aggressive Nonmelanoma Skin Cancers
Presented by: Valencia D. Thomas, Michael K. Wong, and Andrew J. Bishop
. Wong, several ongoing trials are evaluating the role of adjuvant immunotherapy in stage III disease and advanced MCC (ClinicalTrials.gov identifiers: NCT04291885 , NCT02196961 , NCT03798639 , NCT03271372 ). Although much of these data are not yet
Localized Gastroesophageal Cancers: Can We Shift the Current Treatment Paradigms?
Jane E. Rogers, Allison Trail, and Jaffer A. Ajani
approaches (meaning using residual cancer in the surgical specimen to derive an individualized vaccine or a vaccine that would address multiple antigens, adjuvant immunotherapies, bispecific antibodies, bispecific T-cell engagers, antibody drug conjugates
Determining PARP Inhibition as a Treatment Strategy in Melanoma Based on Homologous Recombination Deficiency–Related Loss of Heterozygosity
Alice Zhou, Omar Butt, Michael Ansstas, Elizabeth Mauer, Karam Khaddour, and George Ansstas
extending to the peripheral margin with 3 of the 9 excised lymph nodes positive for metastatic disease. Initial treatment included 30 Gy of hypofractionated radiotherapy followed by adjuvant immunotherapy with nivolumab, 480 mg every 4 weeks. After 4
Targeting PD-L1 After Adjuvant Radiation in Subtotally Resected Primary Pineal Melanoma: A Case Report and Literature Review
Justin Famoso, Gerald Lemole, Srinath Sundararajan, and Baldassarre Stea
maximal safe resection followed by focal radiation and adjuvant immunotherapy is both safe and effective. References 1. Wendel C , Kaech DL , Woodtli M . Primary malignant melanoma in the pineal region: case report and literature review . J
Mutation Testing and Adjuvant Systemic Therapy in Cutaneous Melanoma
Anthony J. Olszanski
exciting results in the adjuvant setting: relapse-free survival was significantly increased in patients with fully resected stage III disease (based on AJCC 7th edition) with a BRAF V600E/K mutation. 7 Adjuvant Immunotherapy The addition of immunotherapy
Page:12
